

JOURNAL SELECTION

NOVEL THERAPEUTIC APPROACHES IN MULTIPLE MYELOMA BEYOND STANDARD THERAPY

Journal Selection Report

Job code	xxxxxxx
Manuscript title	
Date	xxxxx
Author preferences	**Keywords:**
Comments on Adherence to Author Preferences	All recommended journals have regularly published articles on topics related to the authors' Area of Research / Idea

Journal Recommendations

Journal name	Comments
Clinical Lymphoma, Myeloma & Leukemia *Publisher: Elsevier*	**The Reason for the recommendation:** 1. *Clinical Lymphoma, Myeloma & Leukemia* is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of **lymphoma**, **myeloma** and **leukemia**. *Clinical Lymphoma, Myeloma & Leukemia* is devoted to articles on **detection**, **diagnosis**, **prevention**, and **treatment** of lymphoma, myeloma, leukemia and related disorders including **macroglobulinemia**, **amyloidosis**, and **plasma-cell dyscrasias**. 2. The journal published several articles on topics like authors' Area of Research / Idea, e.g., • Jain, J., & Borate, U. (2026). SOHO state of the art updates and next questions | progress in clonal hematopoiesis of indeterminate potential/clonal cytopenia of uncertain significance. *Clinical Lymphoma, Myeloma & Leukemia*, *26*(8), 479–484. https://doi.org/10.1016/j.clml.2026.05.007 • Albano, D., Chauvie, S., Rizzo, A., Bertagna, F., Casadei, B., Vitolo, U., Tucci, A., Zinzani, P. L., & Guerra, L. (2026). The prognostic role of interim [18F] FDG PET/CT in diffuse large B-cell lymphoma: An updated systematic review and meta-analysis. *Clinical Lymphoma, Myeloma & Leukemia*, *26*(8), 491-510.e1. https://doi.org/10.1016/j.clml.2026.06.008

Journal of Hematology & Oncology *Publisher: BioMed Central*	**The Reason for the recommendation:** 1. First launched in 2008, the *Journal of Hematology & Oncology* now ranks in the top quartile of journals worldwide in both closely intertwined and rapidly evolving fields. Encompassing all aspects of hematology and oncology, this peer reviewed, open access journal publishes high-quality articles from leading experts. As the official journal of the Chinese American Hematologist and Oncologist Network (CAHON), we pride ourselves on providing top-class peer review with rapid turnaround times. 2. The journal published several articles on topics like authors' Area of Research / Idea, e.g., • Tan, J., Wen, T., Liu, J. *et al.* Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications. *J Hematol Oncol* (2026). https://doi.org/10.1186/s13045-026-01828-0 • Qiao, L., Wu, L., Xiao, Y. *et al.* From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine. *J Hematol Oncol* (2026). https://doi.org/10.1186/s13045-026-01827-1
Blood Cancer Journal *Publisher: Springer Nature (Nature Portfolio)*	**The Reason for the recommendation:** 1. *Blood Cancer Journal* seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. The *Journal* will consider for publication original research, reviews, guidelines and letters that are of high impact in the field. 2. The journal published several articles on topics like the authors' Area of Research / Idea, e.g., • Liu, L., Sigel, B., Wang, M. *et al.* Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma. *Blood Cancer J.* (2026). https://doi.org/10.1038/s41408-026-01592-x • Afrough, A., Pasvolsky, O., Portuguese, A.J. *et al.* Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium. *Blood Cancer J.* (2026). https://doi.org/10.1038/s41408-026-01565-0

Journal Comparator

Key Parameters		Clinical Lymphoma, Myeloma & Leukaemia	Journal of Hematology & Oncology	Blood Cancer Journal
Publisher		Elsevier	BioMed Central	Springer Nature (Nature Portfolio)
Similar research published		Yes	Yes	Yes
Indexing database		PubMed/MEDLINE, Scopus, Embase	PubMed, MEDLINE, PubMed Central, Scopus, Science Citation Index Expanded (SCIE), DOAJ	Web of Science, Scopus, PubMed Central, and DOAJ.
Impact factor		4.1	47.8	13.8
Review duration		Not Mentioned	8 Days	6 Days
Publication type		Peer-reviewed monthly journal	Open access peer-reviewed	Fully open access online
Rejection rate		Not Mentioned	Not Mentioned	
Acceptance rate		Not Mentioned	Not Mentioned	
Article processing charges		Approximately $3,670 to $3,780 USD	$4,390 / €3,690	$5,490 / £3,690 / €4,390
Limit	**Word count**	2,000 to 8,000 words	3,000 to 4,000 words	4,000–5,000 words
	Figure/Tables	8 figures and tables	maximum of 2 figures or tables	8 Tables or figures.
	References	80 References	12 References	60 References

Supporting Information - Rationale for Inclusion and Scope

Clinical Lymphoma, Myeloma & Leukemia	
Rationale for inclusion	Included because it focuses on hematological malignancies, particularly lymphoma, multiple myeloma, and leukemia. The journal is highly relevant for publishing research and reviews on emerging therapeutic strategies, novel drugs, and advances in the management of multiple myeloma.
Scope	The journal covers clinical and translational research in hematologic cancers, including multiple myeloma, lymphomas, leukemias, targeted therapies, immunotherapies, stem cell transplantation, clinical trials, and new treatment approaches.

Journal of Hematology & Oncology	
Rationale for inclusion	Included because it is a leading international journal in hematology and oncology that publishes high-quality research and reviews on innovative cancer therapies. It is suitable for articles discussing novel therapeutic approaches and advances beyond conventional treatment strategies in multiple myeloma.
Scope	The journal covers basic, translational, and clinical research in hematological malignancies and solid tumors, including molecular mechanisms, targeted therapies, immunotherapy, precision medicine, cancer biology, and innovative treatment approaches.

Blood Cancer Journal	
Rationale for inclusion	Included because it focuses on blood cancers and publishes significant advances in the diagnosis, biology, and treatment of hematologic malignancies. It is relevant for reviews and research on novel therapeutic developments in multiple myeloma.
Scope	The journal covers research on hematological cancers, including multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes, molecular mechanisms, biomarkers, immunotherapies, targeted treatments, and emerging therapeutic strategies.

Appendix: Frequently Asked Questions

Q1. What is Multiple Myeloma?

Answer: Multiple Myeloma is a type of blood cancer that develops from abnormal plasma cells in the bone marrow. These malignant plasma cells produce abnormal proteins and can cause bone damage, anemia, kidney problems, weakened immunity, and other complications.

Q2. What are the common symptoms of Multiple Myeloma?

Answer: Common symptoms include bone pain (especially in the back and ribs), fatigue, weakness, frequent infections, anemia, high calcium levels, kidney dysfunction, and unexplained weight loss. Some patients may remain asymptomatic during early stages.

Q3. What are the standard treatments for Multiple Myeloma?

Answer: Standard treatments include combinations of chemotherapy, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, corticosteroids, and autologous stem cell transplantation. Treatment selection depends on patient age, disease stage, and overall health status.

Q4. What are the novel therapeutic approaches being explored in Multiple Myeloma?

Answer: Novel approaches include CAR-T cell therapy, bispecific antibodies, antibody–drug conjugates, targeted therapies, next-generation immunotherapies, and personalized medicine strategies. These treatments aim to improve outcomes, especially in patients with relapsed or refractory disease.

Q5. Can Multiple Myeloma be cured?

Answer: Currently, Multiple Myeloma is considered a chronic and generally incurable disease; however, advances in therapy have significantly improved survival and quality of life. New therapeutic approaches continue to provide deeper and more durable responses for many patients.